An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Defitelio

Chemical Namedefibrotide sodium
Dosage FormInjection (intravenous; 200 mg/2.5 mL)
Drug ClassOligonucleotides
SystemDigestive
CompanyJazz Pharmaceuticals Inc.
Approval Year2016

Indication

  • To treat adults and children who develop hepatic veno-occlusive disease with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Defitelio (defibrotide sodium) Prescribing Information 2016Jazz Pharmaceuticals, Inc. Palo Alto, CA
Document TitleYearSource
Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). 2019Bone Marrow Transplantation
Efficacy and safety of defibrotide for the treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review and meta-analysis. 2019Seminars in Thrombosis & Hemostasis